ArticleApplied and environmental microbiology2021
A Bioengineered Nisin Derivative To Control Streptococcus uberis Biofilms.
Article in Applied and environmental microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Biotope-dependent resistance to reactive oxygen species, antibiotic tolerance, and virulence of Staphylococcus aureus.Communications biology · 2026Article
- Do We Need to Worry About Staphylococcus epidermidis ST0409KOC, a Cheese-Isolated Strain With Bacteriocinogenic Properties?Molecular nutrition & food research · 2026Article
- The Effects of Low Concentrations of Nisin on Biofilm Formation byPathogens (Basel, Switzerland) · 2025Article
- Biofilm Resilience: Molecular Mechanisms Driving Antibiotic Resistance in Clinical Contexts.Biology · 2025Review
- Guarding the walls: the multifaceted roles of Bce modules in cell envelope stress sensing and antimicrobial resistance.Journal of bacteriology · 2024Review
- When the solution becomes the problem: a review on antimicrobial resistance in dairy cattle.Future microbiology · 2024Review
- Pharmacological composition based on bacteriocinnisin in experimentsOpen veterinary journal · 2024Article
- Bovine mastitis, a worldwide impact disease: Prevalence, antimicrobial resistance, and viable alternative approaches.Veterinary and animal science · 2023Review
- Engineering of Nisin as a Means for Improvement of Its Pharmacological Properties: A Review.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Protective Cultures in Food Products: From Science to Market.Foods (Basel, Switzerland) · 2023Review
- Bioengineered Nisin A Derivatives Display Enhanced Activity against Clinical Neonatal Pathogens.Antibiotics (Basel, Switzerland) · 2022Article
- Four Novel Leaderless Bacteriocins, Bacin A1, A2, A3, and A4 Exhibit Potent Antimicrobial and Antibiofilm Activities against Methicillin-Resistant Staphylococcus aureus.Microbiology spectrum · 2022Article
- Isolation, Characterization, and Effect on Biofilm Formation of Bacteriocin Produced byBioMed research international · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial peptides are evolving as novel therapeutic options against the increasing problem of multidrug-resistant microorganisms, and nisin is one such avenue. However, some bacteria possess a specific nisin resistance system (NSR), which cleaves the peptide reducing its bactericidal efficacy. NSR-based resistance was identified in strains of Streptococcus uberis, a ubiquitous pathogen that causes mastitis in dairy cattle. Previous studies have demonstrated that a nisin A derivative termed nisin PV, featuring S29P and I30V, exhibits enhanced resistance to proteolytic cleavage by NSR. Our objective was to investigate the ability of this nisin derivative to eradicate and inhibit biofilms of S. uberis DPC 5344 and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.